EP0358724A1 - Compound, composition and method for the reduction of lipids the modification of the affinity of hemoglobin for oxygen and the prevention of platelet aggregation - Google Patents

Compound, composition and method for the reduction of lipids the modification of the affinity of hemoglobin for oxygen and the prevention of platelet aggregation

Info

Publication number
EP0358724A1
EP0358724A1 EP88906435A EP88906435A EP0358724A1 EP 0358724 A1 EP0358724 A1 EP 0358724A1 EP 88906435 A EP88906435 A EP 88906435A EP 88906435 A EP88906435 A EP 88906435A EP 0358724 A1 EP0358724 A1 EP 0358724A1
Authority
EP
European Patent Office
Prior art keywords
carbon atoms
compound
hemoglobin
straight
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP88906435A
Other languages
German (de)
French (fr)
Other versions
EP0358724A4 (en
Inventor
Iraj Lalezari
Samuel Rahbar
Parviz Lalezari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0358724A1 publication Critical patent/EP0358724A1/en
Publication of EP0358724A4 publication Critical patent/EP0358724A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the applicants have discovered a new class of phenylureido substituted phenoxy propionic acid compounds which can be administered orally to mammals to reduce total blood cholesterol levels and low density lipid-cholesterol levels without substantially affecting high density lipid- cholesterol levels.
  • the compounds may also be utilized to modify the affinity of hemoglobin for oxygen or to prevent platelet aggregation.
  • R 1 , R 2 , R 3 and R 4 may be the same or different and independently selected from the group consisting of hydrogen, halogen, straight and branched chain alkyl of from 1-6 carbon atoms, aryl, cycloalkyl of 4 to 7 carbon atoms; and alkoxy of
  • R 5 and R 6 may be the same or different and are selected from the group consisting of hydrogen, halogen, straight and branched chain alkyl groups of from 1-6 carbon atoms, aralkyl groups wherein the alkyl portion has from 1-6 carbon atoms cycloalkyl of from 4-7 carbon atoms and aryl;
  • R 7 is hydrogen or a straight or branched chain alkyl group of 1-6 carbon atoms and the pharmaceutically acceptable salts such as the sodium, potassium, ammonium, etc.
  • the invention also includes pharmaceutical compositions that are based on a compound of Formula I and methods for the reduction of hyperlipidemia by the oral administration of a comoound of Formula I.
  • FIG. 1 shows the effects of a compound of the invention on the oxygen dissociation of human hemoglobin solution.
  • FIG. 2 shows the effects of a compound of the invention on the oxygen dissociation of intact human red blood cells.
  • the nitrophenoxy acid is prepared according to the procedure described by P. Galimberti et al., Gazz. Chim. Ital. 77,431 (1947).
  • the amino substituted compound is prepared by catalytic hydrogenation of the nitro compound according to the procedure of G.E. Wicks, Jr., J. Med. Chem. 15,436 (1972).
  • the amino substituted compound is then reacted with an arylisocyanate to form the arylureido acid compound of the invention.
  • the esters of the free acid are formed by reacting the appropriate alcohol with the free acid using conventional ester forming conditions.
  • the pharmaceutically acceptable salts may be prepared by standard procedures using the appropriate metal or ammonium salt such as sodium hydroxide, sodium bicarbonate, potassium hydroxide and the like.
  • the compounds of the invention may be administered to mammals including humans to reduce or prevent hyperlipidemia especially to reduce the levels of total serum cholesterol, low density lipoprotein-associated cholesterol and trigly- cerides.
  • the compounds may be administered orally at a daily dosage of frdm about 1 to 200 mg per kilogram of body weight and more preferably at a level of about 10 to 50 mg per kilogram of body weight.
  • the daily dosage is to be administered as a single dose, or in divided amounts three or four times a day. It is understood that the dose may be varied according to individual sensitivity and the type of hyperlipidemia being treated.
  • the compounds may be administered parenterally or rectally. The parenteral dose will be 15-25% of the oral dosage and the rectal dosage may be adjusted to obtain the desired therapeutic affect.
  • the compounds of the invention may be added to whole blood or packed cells in an amount of about 50mg to 2.0g per unit of blood (473ml) or unit of packed cells (235ml) and preferably from 250mg to 750mg per unit of blood or unit of packed cells in order to facilitate the dissociation of oxygen from hemoglobin and improve the oxygen delivery capability of blood.
  • the hemoglobin in the blood tends to increase its affinity for oxygen by losin 2,3-diphosphoglycerides.
  • the compounds of the invention are capable of reversing and/or preventing the functional abnormality of hemoglobin which is observed when whole blood or packed cells are stored.
  • the compounds of the invention may be added to whole blood or red blood cell fractions in a closed system using an appropriate resevoir in which the compound is placed prior to storage or which is present in the anticoagulating solution in the blood collecting bag.
  • the compounds may be administered to patients in whom the affinity of hemoglobin for oxygen is abnormally high (e.g. certain hemoglobinopathies), or when the availability of hemoglobin to tissues is decreased, (e.g. in ischemic conditions such as peripheral vascular disease, coronary occlusion or cerebral vascular accidents).
  • the compounds may also be used to inhibit platelet aggregation and may be used for antithrombotic purposes.
  • the dosage for the modification of the affinity of hemoglobin for oxygen may be based on the dosages set forth above for hyperlipidemia and these dosages may be adjusted for parenteral use to obtain the desired therapeutic result.
  • the compounds should not be administered to patients with sickle cell disease to avoid the possibility of excessive oxygen loss which may precipitate a sickle cell crisis.
  • halogen is used to include bromo, chloro, fluoro and iodo
  • alkyl includes straight and branched chain hydrocarbon groups of 1-6 carbon atoms such as methyl, ethyl, n-propyl, n-pentyl and the like
  • aryl includes phenyl and naphthyl
  • cycloalkyl includes cycloaliphatic groups of 4 to 7 carbon atoms such a cyclobutyl, cyclopentyl, cyclohexyl and the like
  • alkoxy is used to include R 8 OH groups wherein R 8 is alkyl of 1 to 6 carbon atoms
  • aralkyl is used to include phenalkyl groups wherein the alkyl portion is an alkylene moiety of 1-6 carbons such as benzyl, phenethyl, phenpropyl and the like.
  • pharmaceutically acceptable diluent is used to include liquid and solid materials conventionally utilized to prepare injectable dosage forms and solid dosage forms such as tablets and capsules.
  • Water may be used for the preparation of injectable compositions which may also include conventional buffers and agents to render the injectable composition isotonic
  • the solid diluents and excipients include lactose, starch, conventional disintegrating agents, coatings and the like.
  • UK patent 1,535,683 which is incorporated by reference, gives several embodiments of formulation that may be utilized in the preparation of tablets and capsules.
  • nitrophenoxy 2-methyl propionic acid intermediate was prepared by the reaction of chlorofrom with 4-nitrophenol and sodium hydroxide in dry acetone as described by P. Galimberti and A. Defranceschi, Gazz. Chim. Ital. 77, 431, (1947). The yield was 54%. mp 121-123°. (recrystallized from CCl 4 ).
  • the amino phenoxy hydrochloride compound was prepared by catalytic hydrogenation of the nitro compound as described by H. Z. Sommer and G. E. Wicks, Jr., J. Med. Chem. 15, 436 (1972).
  • the free base required for the synthesis of phenylureido derivatives was obtained by alkalinization of the hydrochloride with IN NaOH followed by the addition of concentrated acetic acid to precipitate the free acid as a crystalline compound, mp 214-216°.
  • FIG. 1 illustrates the oxygen dissociation curves produced by a 50 uM solution of normal human hemoglobin tested at pH 7.2 using TRIS as the buffer in a Hemox analyzer. In this test, percent oxygen saturation (on the vertical axis) is plotted against the partial pressure of oxygen (pO 2 in the horizontal axis).
  • Curve #1 shows the normal oxygen dissociation curve in the absence of any modifying agent.
  • Curve #2 shows a shift to the right when 5mM Bezafibrate that was solubilized with an equimolar amount of sodium bicarbonate is added.
  • Curve #3 shows the right shift caused by 1mM concentration of the compound of Example 3 that was solubilized with an equimolar amount of sodium bicarbonate and curve #4 shows the shift affected by the presence of 0.5mM of the compound of Example 3.
  • Fig. 2 illustrates the same effects when the intact human RBCs are treated with the same compounds.
  • 50 uL washed human RBCs were suspended in 4ml of HEPES buffer (pH 7.4) and oxygen dissociation curves were obtained.
  • Curve #1 shows the oxyge dissociation curve produced by Hb in untreated RBCs.
  • Curve #2 illustrates the right shift caused by the presence of 5mM Bezafibrate.
  • This example describes the cholesterol and lipoprotein reducing activities of the compounds of the invention.
  • Animals in Group one received normal rat diet.
  • Nath's diet is composed of 49% sucrose, 24% coconut oil, 18% casein, vitamin mixture 2%, Maize oil 1%, Mineral salts 4%, cholic acid 1%, and cholesterol 1%.
  • Animals in Group two received no medications and served as hyperlipemic controls.
  • Animals in Group 3 received 30 mg/kg/day of the compound of Example 3 mixed with their food. At the end of fifteen days all the animals were sacrificed and their blood cholesterol and lipids were measured. The results are as follows:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nouveaux composés de formule (I) dans laquelle R2, R2, R3 et R4 peuvent être identiques ou différents et choisis indépendamment dans le groupe composé d'un hydrogène, halogène, alkyle à chaîne droite ou ramifiée de 1 à 6 atomes de carbone, aryle, cycloalkyle de 4 à 7 atomes de carbone; et alkoxy de 1 à 6 atomes de carbone; R5 et R6 peuvent être identiques ou différents et sont choisis dans le groupe composé d'un hydrogène, halogène, de groupes alkyle à chaîne droite ou ramifiée de 1 à 6 atomes de carbone, de groupes aralkyle où la portion alkyle possède de 1 à 6 atomes de carbone, cycloalkyle de 4 à 7 atomes de carbone et aryle; R7 est hydrogène ou un groupe alkyle à chaîne droite ou ramifiée de 1 à 6 atomes de carbone. Sont également décrits leurs sels pharmaceutiquement acceptables. Ces composés sont utiles pour le traitement de l'hyperlipidémie et pour le traitement in vivo et in vitro de l'hémoglobine ou du sang en vue de modifier l'affinité de l'hémoglobine pour l'oxygène.New compounds of formula (I) in which R2, R2, R3 and R4 may be the same or different and independently selected from the group consisting of hydrogen, halogen, straight or branched chain alkyl of 1 to 6 carbon atoms, aryl , cycloalkyl of 4 to 7 carbon atoms; and alkoxy of 1 to 6 carbon atoms; R5 and R6 may be the same or different and are chosen from the group consisting of hydrogen, halogen, straight or branched chain alkyl groups of 1 to 6 carbon atoms, aralkyl groups in which the alkyl portion has from 1 to 6 carbon atoms, cycloalkyl of 4 to 7 carbon atoms and aryl; R7 is hydrogen or a straight or branched chain alkyl group of 1 to 6 carbon atoms. Also described are their pharmaceutically acceptable salts. These compounds are useful for the treatment of hyperlipidemia and for the in vivo and in vitro treatment of hemoglobin or blood to modify the affinity of hemoglobin for oxygen.

Description

COMPOUND, COMPOSITION AND METHOD FOR THE REDUCTION OF LIPIDS THE MODIFICATION OF THE AFFINITY OF HEMOGLOBIN FOR OXYGEN AND THE PREVENTION OF PLATELET AGGREGRATION
BACKGROUND OF THE INVENTION Many compounds have been described which are useful for the reduction of serum lipid levels. A number of these compounds are commercially available for the treatment of hyperlipidemia. Some of these compounds are disclosed in U.S. 3,781,327; U.S. 3,907,792; U.S. 3,948,973; U.S. 4,126,637; UK 860,303; UK 1,535,683; and U.S. 3,262,850 all of which are incorporated by references. In addition, it was known that bezafibrate, an antihyperlipoproteinemia drug was capable of lowering the oxygen affinity of hemoglobin A Perutz et al. JACS 108, 1064-1068 (1986). The compound theofibcate is known to have antilipemic, antithrombotic and platelet aggregation inhibitory activities.
The applicants have discovered a new class of phenylureido substituted phenoxy propionic acid compounds which can be administered orally to mammals to reduce total blood cholesterol levels and low density lipid-cholesterol levels without substantially affecting high density lipid- cholesterol levels. The compounds may also be utilized to modify the affinity of hemoglobin for oxygen or to prevent platelet aggregation.
Accordingly, it is a primary object of this invention to provide novel phenylureido substituted phenoxy propionic acid compounds that may be used to reduce blood lipids.
It is also an object of this invention to provide a novel pharmaceutical composition containing phenylureido substituted phenoxy propionic acid compounds. It is also an object of this invention to provide a novel method for the treatment of hyperlipidemia in mammals which is based on the administration of a phenylureido substituted phenoxypropionic acid.
It is also an object of the invention to modify the affinity of hemoglobin for oxygen.
It is also an object of this invention to provide a method for preventing platelet aggregation.
SUMMARY OF THE INVENTION The invention is concerned with novel compounds of the formula:
wherein R1, R2, R3 and R4 may be the same or different and independently selected from the group consisting of hydrogen, halogen, straight and branched chain alkyl of from 1-6 carbon atoms, aryl, cycloalkyl of 4 to 7 carbon atoms; and alkoxy of
1 to 6 carbon atoms; R5 and R6 may be the same or different and are selected from the group consisting of hydrogen, halogen, straight and branched chain alkyl groups of from 1-6 carbon atoms, aralkyl groups wherein the alkyl portion has from 1-6 carbon atoms cycloalkyl of from 4-7 carbon atoms and aryl; R7 is hydrogen or a straight or branched chain alkyl group of 1-6 carbon atoms and the pharmaceutically acceptable salts such as the sodium, potassium, ammonium, etc.
The invention also includes pharmaceutical compositions that are based on a compound of Formula I and methods for the reduction of hyperlipidemia by the oral administration of a comoound of Formula I. BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows the effects of a compound of the invention on the oxygen dissociation of human hemoglobin solution.
FIG. 2 shows the effects of a compound of the invention on the oxygen dissociation of intact human red blood cells.
DETAILED DESCRIPTION OF THE INVENTION The novel compounds of the invention may be prepared by the following general procedure:
The nitrophenoxy acid is prepared according to the procedure described by P. Galimberti et al., Gazz. Chim. Ital. 77,431 (1947). The amino substituted compound is prepared by catalytic hydrogenation of the nitro compound according to the procedure of G.E. Wicks, Jr., J. Med. Chem. 15,436 (1972). The amino substituted compound is then reacted with an arylisocyanate to form the arylureido acid compound of the invention. The esters of the free acid are formed by reacting the appropriate alcohol with the free acid using conventional ester forming conditions. The pharmaceutically acceptable salts may be prepared by standard procedures using the appropriate metal or ammonium salt such as sodium hydroxide, sodium bicarbonate, potassium hydroxide and the like.
The compounds of the invention may be administered to mammals including humans to reduce or prevent hyperlipidemia especially to reduce the levels of total serum cholesterol, low density lipoprotein-associated cholesterol and trigly- cerides. The compounds may be administered orally at a daily dosage of frdm about 1 to 200 mg per kilogram of body weight and more preferably at a level of about 10 to 50 mg per kilogram of body weight. The daily dosage is to be administered as a single dose, or in divided amounts three or four times a day. It is understood that the dose may be varied according to individual sensitivity and the type of hyperlipidemia being treated. In addition the compounds may be administered parenterally or rectally. The parenteral dose will be 15-25% of the oral dosage and the rectal dosage may be adjusted to obtain the desired therapeutic affect.
The compounds of the invention may be added to whole blood or packed cells in an amount of about 50mg to 2.0g per unit of blood (473ml) or unit of packed cells (235ml) and preferably from 250mg to 750mg per unit of blood or unit of packed cells in order to facilitate the dissociation of oxygen from hemoglobin and improve the oxygen delivery capability of blood. When blood is stored, the hemoglobin in the blood tends to increase its affinity for oxygen by losin 2,3-diphosphoglycerides. The compounds of the invention are capable of reversing and/or preventing the functional abnormality of hemoglobin which is observed when whole blood or packed cells are stored. The compounds of the invention may be added to whole blood or red blood cell fractions in a closed system using an appropriate resevoir in which the compound is placed prior to storage or which is present in the anticoagulating solution in the blood collecting bag.
It may be desirable to administer the compound to a patient prior to and/or simultaneously with the transfusion of the treated whole blood or red cells in order to avoid substantial variations in the hemoglobin oxygen affinity due to dilution that occurs when the blood is administered.
The compounds may be administered to patients in whom the affinity of hemoglobin for oxygen is abnormally high (e.g. certain hemoglobinopathies), or when the availability of hemoglobin to tissues is decreased, (e.g. in ischemic conditions such as peripheral vascular disease, coronary occlusion or cerebral vascular accidents). The compounds may also be used to inhibit platelet aggregation and may be used for antithrombotic purposes. The dosage for the modification of the affinity of hemoglobin for oxygen may be based on the dosages set forth above for hyperlipidemia and these dosages may be adjusted for parenteral use to obtain the desired therapeutic result. The compounds should not be administered to patients with sickle cell disease to avoid the possibility of excessive oxygen loss which may precipitate a sickle cell crisis.
As used herein the term halogen is used to include bromo, chloro, fluoro and iodo; the term alkyl includes straight and branched chain hydrocarbon groups of 1-6 carbon atoms such as methyl, ethyl, n-propyl, n-pentyl and the like; the term aryl includes phenyl and naphthyl; the term cycloalkyl includes cycloaliphatic groups of 4 to 7 carbon atoms such a cyclobutyl, cyclopentyl, cyclohexyl and the like; the term alkoxy is used to include R8OH groups wherein R8 is alkyl of 1 to 6 carbon atoms; the term aralkyl is used to include phenalkyl groups wherein the alkyl portion is an alkylene moiety of 1-6 carbons such as benzyl, phenethyl, phenpropyl and the like.
The term pharmaceutically acceptable diluent is used to include liquid and solid materials conventionally utilized to prepare injectable dosage forms and solid dosage forms such as tablets and capsules. Water may be used for the preparation of injectable compositions which may also include conventional buffers and agents to render the injectable composition isotonic The solid diluents and excipients include lactose, starch, conventional disintegrating agents, coatings and the like. For example, UK patent 1,535,683, which is incorporated by reference, gives several embodiments of formulation that may be utilized in the preparation of tablets and capsules.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The compounds of the invention, their preparation and use are more particularly illustrated by the following examples.
EXAMPLE 1
The nitrophenoxy 2-methyl propionic acid intermediate was prepared by the reaction of chlorofrom with 4-nitrophenol and sodium hydroxide in dry acetone as described by P. Galimberti and A. Defranceschi, Gazz. Chim. Ital. 77, 431, (1947). The yield was 54%. mp 121-123°. (recrystallized from CCl4).
The amino phenoxy hydrochloride compound was prepared by catalytic hydrogenation of the nitro compound as described by H. Z. Sommer and G. E. Wicks, Jr., J. Med. Chem. 15, 436 (1972).
The free base required for the synthesis of phenylureido derivatives was obtained by alkalinization of the hydrochloride with IN NaOH followed by the addition of concentrated acetic acid to precipitate the free acid as a crystalline compound, mp 214-216°.
To a stirring solution of 2-(4-aminophenoxy)-2- methylpropionic acid, 0.975g (5 mmoles) in 5 ml IN NaOH, cooled to ice salt bath temperature, 0.543 ml (5 mmoles) of phenylisocyanate was dropwise added. Stirring continued overnight at room temperature. Water, 15 ml was added and pH adjusted to 10 by the addition of IN NaOH. The solution was charcoaled and filtered. It was acidified with hydrochloric acid. The white precipitate was filtered, washed with water and dried. It was recrystallized from aqueous acetone (charcoaled) to colorless shining plates, mp 195-196°. (Yield 94%).
EXAMPLE 2 To a stirred solution of 2-(4-aminophenoxy)-2- methylpropionic acid, 0.975g (5 mmoles) in 5 ml IN NaOH (5 mmoles) and cooled to ice bath temperature, a solution of 0.767g 4-chlorophenylisocyanate in 10 ml tetrahydrofuran was dropwise added. Stirring continued 2 hours at room temperature. It was then diluted with 20 ml water, charcoaled, and filtered. Acidification (HCl) gave a gray powder. It was recrystallized from aqueous acetone (charcoaled) as small colorless plates. mp 222-223°. (Yield 86%).
EXAMPLE 3 To a solution of 2-(4-aminophenoxy)-2-methylpropionic acid, 0.975g (5 mmoles) in 5 ml IN NaOH (5 mmoles), cooled to ice salt bath temperature, a solution of 0.94 (5 mmoles) of 3,4-dichlorophenylisocyanate in 10 ml tetrahydrofuran was dropwise added. The stirring was continued for two hours at room temperature. To the reaction product, 20 ml water was added, charcoaled and filtered. Acidification with hydrochloric acid gave a light brown crystalline compound. It was recrystallized twice (charcoaled) from aqueous acetone to give large silvery plates. mp 184-185. (Yield 80%).
All compounds prepared were checked by TLC for the purity. The structure elucidation was based on NMR and IR spectroscopy and elemental analysis.
EXAMPLE 4 Fig. 1 illustrates the oxygen dissociation curves produced by a 50 uM solution of normal human hemoglobin tested at pH 7.2 using TRIS as the buffer in a Hemox analyzer. In this test, percent oxygen saturation (on the vertical axis) is plotted against the partial pressure of oxygen (pO2 in the horizontal axis). Curve #1 shows the normal oxygen dissociation curve in the absence of any modifying agent. Curve #2 shows a shift to the right when 5mM Bezafibrate that was solubilized with an equimolar amount of sodium bicarbonate is added. Curve #3 shows the right shift caused by 1mM concentration of the compound of Example 3 that was solubilized with an equimolar amount of sodium bicarbonate and curve #4 shows the shift affected by the presence of 0.5mM of the compound of Example 3. Fig. 2 illustrates the same effects when the intact human RBCs are treated with the same compounds. In this example, 50 uL washed human RBCs were suspended in 4ml of HEPES buffer (pH 7.4) and oxygen dissociation curves were obtained. Curve #1 shows the oxyge dissociation curve produced by Hb in untreated RBCs. Curve #2 illustrates the right shift caused by the presence of 5mM Bezafibrate. The effects of 1mM and 0.5mM of the compound of Example 3 are shown in curves #3 and #4 respectively. Curve #5 was obtained after the RBCs that had been mixed with ImM of the compound of Example 3 that was solubilized with an equimolar amount of sodium bicarbonate were washed once and then retested. This example illustrates that the effects of the compound of Example 4 can be reversed by washing. EXAMPLE 5
This example describes the cholesterol and lipoprotein reducing activities of the compounds of the invention. Three groups of Sprague Dawley rats (five in each group) and each weighing 200g were studied. Animals in Group one received normal rat diet. Animals in Groups two and three received Nath's diet for 15 days. Nath's diet is composed of 49% sucrose, 24% coconut oil, 18% casein, vitamin mixture 2%, Maize oil 1%, Mineral salts 4%, cholic acid 1%, and cholesterol 1%. Animals in Group two received no medications and served as hyperlipemic controls. Animals in Group 3 received 30 mg/kg/day of the compound of Example 3 mixed with their food. At the end of fifteen days all the animals were sacrificed and their blood cholesterol and lipids were measured. The results are as follows:
Total Cholesterol Trigly HDL-Chol. LDL-Chol.
Normal Diet 53±10 45±12 42±13 5±5
Nath Diet 162±48 120±41 72±25 66±40
Nath Diet and 117±22 104±25 65±31 32±34
Compound of Example 3
These data show significant reduction in total cholesterol and LDL-cholestrol in the compound of Example 3 treated animals despite a highly challenging lipid-rich diet.

Claims

WE CLAIM:
1. A compound of the formula:
wherein R1, R2, R3 and R4 may be the same or different and independently selected from the group consisting of hydrogen, halogen, straight and branched chain alkyl of from 1-6 carbon atoms, aryl, cycloalkyl of 4 to 7 carbon atoms; and alkoxy of 1 to 6 carbon atoms; R5 and R6 may be the same or different and are selected from the group consisting of hydrogen, halogen, straight and branched chain alkyl groups of from 1-6 carbon atoms, aralkyl groups wherein the alkyl portion has from 1-6 carbon atoms cycloalkyl of from 4-7 carbon atoms and aryl; R7 is hydrogen or a straight or branched chain alkyl group of 1-6 carbon atoms and the pharmaceutically acceptable salts thereof.
2. A compound as defined in Claim 1 which is 2-(4-(phenylureido)-phenoxy)-4-methylproρionic acid.
3. A compound as defined in Claim 1 which is 2- 2-(4-(chlorophenylureido)phenoxy)-2-methylpropionic acid.
4. A compound as defined in Claim 1 which is 2-(4-(3,4-dichlorophenylureido)phenoxy)-2-methylpropionic acid.
5. A compound as defined in Claim 1 which is the sodium salt of 2-(4-(3,4-dichlorophenylureido)phenoxy)-2- methylpropionic acid.
6. A pharmaceutical composition which comprise a compound of the formula:
wherein R1, R2, R3 and R4 may be the same or different and independently selected from the group consisting of hydrogen, halogen, straight and branched chain alkyl of from 1-6 carbon atoms, aryl, cycloalkyl of 4 to 7 carbon atoms; and alkoxy of 1 to 6 carbon atoms; R5 and R6 may be the same or different and are selected from the group consisting of hydrogen, halogen, straight and branched chain alkyl groups of from 1-6 carbon atoms, aralkyl groups wherein the alkyl portion has from 1-6 carbon atoms cycloalkyl of from 4-7 carbon atoms an aryl; R7 is hydrogen or a straight or branched chain alkyl group of 1-6 carbon atoms and the pharmaceutically acceptable salts thereof and a pharmaceutically acceptable diluent.
7. A pharmaceutical composition as defined in Claim 6 wherein the compound is 2-(4-(phenylureido)phenoxy)- 2-methylpropionic acid.
8. A pharmaceutical composition as defined in Claim 6 wherein the compound is 2-(4-chloroρhenylureido)- phenoxy)-2-methylpropionic acid.
9. A pharmaceutical composition as defined in
Claim 6 wherein the compound is 2-(4-(3,4-dichlorophenylureido)- phenoxy)-2-methylpropionic aicd.
10. A method for the treatment of hyperlipidemia in a mammal which comprises administering a compound of Claim 1.
11. A method for treating hemoglobin or blood in vivo or in vitro to modify the affinity of hemoglobin for oxygen, said method comprising causing an effective amount of the compound of Claim 1 to come in contact with hemoglobin.
EP19880906435 1987-06-15 1988-06-15 Compound, composition and method for the reduction of lipids the modification of the affinity of hemoglobin for oxygen and the prevention of platelet aggregation. Withdrawn EP0358724A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6223687A 1987-06-15 1987-06-15
US62236 1998-04-17

Publications (2)

Publication Number Publication Date
EP0358724A1 true EP0358724A1 (en) 1990-03-21
EP0358724A4 EP0358724A4 (en) 1990-06-05

Family

ID=22041101

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19880906435 Withdrawn EP0358724A4 (en) 1987-06-15 1988-06-15 Compound, composition and method for the reduction of lipids the modification of the affinity of hemoglobin for oxygen and the prevention of platelet aggregation.

Country Status (4)

Country Link
EP (1) EP0358724A4 (en)
JP (1) JPH02503797A (en)
AU (1) AU616674B2 (en)
WO (1) WO1988010113A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921997A (en) * 1988-06-15 1990-05-01 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses
US5049695A (en) * 1990-02-12 1991-09-17 Center For Innovative Technology Allosteric hemoglobin modifiers
US5382680A (en) * 1990-12-07 1995-01-17 The Center For Innovative Technology Allosteric hemoglobin modifier compounds
GB9027023D0 (en) * 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
WO1994021599A1 (en) * 1993-03-17 1994-09-29 Meiji Seika Kabushiki Kaisha Novel compound with platelet aggregation inhibitor activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2614045A1 (en) * 1976-04-01 1977-10-06 Boehringer Mannheim Gmbh Hypolipaemic ureido-alkyl-phenoxy-alkanoic aid derivs. prepn. - by reacting (4)-hydroxy-aralkylamines with phosgene, amine and halo-alkanoic acid deriv.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. MED. CHEM., vol. 32, no. 12, December 1989, pages 2352-2357, American Chemical Society; I. LALEZARI et al.: "Synthesis and investigation of effects of 2-[4-ÄÄ(Arylamino)carbonylÜaminoÜphenoxyÜ-2-methylpropionic acids on the affinity of hemoglobin for oxygen: Structure-activity relationships" *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 85, August 1988, pages 6117-6121; I. LALEZARI et al.: "LR16, a compound with potent effects on the oxygen affinity of hemoglobin, on blood cholestrol, and on low density lipoprotein" *
See also references of WO8810113A1 *

Also Published As

Publication number Publication date
WO1988010113A1 (en) 1988-12-29
AU616674B2 (en) 1991-11-07
JPH02503797A (en) 1990-11-08
EP0358724A4 (en) 1990-06-05
AU1998688A (en) 1989-01-19

Similar Documents

Publication Publication Date Title
JP3231042B2 (en) Nitrate ester of 2- (2,6-di-halo-phenylamino) phenylacetic acid derivative and method for producing the same
KR0159095B1 (en) Benzoylguanidines, process for their preparation, their use as medicaments as well as medicament containing them
JPH069545A (en) O-substituted benzoylguanidine, its production, its use as medicine or diagnostic agent, and medicine containing it
US5268500A (en) Compound, composition and method for the reduction of lipids the modification of the affinity of hemoblogin for oxygen and the prevention of platelet aggregation
US4921997A (en) Method of synthesis and novel compounds for pharmaceutical uses
EP0345038A2 (en) Non-beta-oxidizable fatty acid analogues with the effect to reduce the concentration of cholesterol and triglycerides in blood of mammals
GB2051779A (en) Esters of acyl-carnitines
US4743611A (en) Naphthalenylsulfonylimidazolidinediones and their thioxo analogs useful as aldose reductase inhibitors
CA2129430C (en) N, n'-substituted imidocarbonimidic diamides derived from hydroxylamines
US4925968A (en) N-acyl-N-naphthoylglycines as aldose reductase inhibitors
AU616674B2 (en) Compound, composition and method for the reduction of lipids the modification of the affinity of hemoglobin for oxygen and the prevention of platelet aggregation
US5292935A (en) Method of synthesis and novel compounds for pharmaceutical uses
SK319892A3 (en) N-phenyl-2-cyano-3-hydroxycrotonamide derivatives, method of their poduction and their using for manufacture of medicines with immunomodulating effect
JPS5925794B2 (en) Heterocyclylcarbonyl derivatives of urea
US4367235A (en) 2-Benzimidazolinone compounds and therapeutic compositions
US4233310A (en) Antiarteriosclerotic N-(mercaptoacyl)-histidines
EP0134337A1 (en) Substituted 2,2-dimethyl-5-phenoxypentanoic acid benzamides and their production
JPS61286359A (en) N-((5-(trifluoromethyl)-6-methoxy-1-naphthalenyl) thioxomethyl or carbonyl)-n-methylglycineamide
IE63412B1 (en) Novel n-(substituted aryl)-n'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents
US3732295A (en) Trimethoxybenzoyl-aminoalkanoic acids
US4514390A (en) Melaminylthioarsenites
JPS6322565A (en) Naphthalenylsulfonylimidazolidinedione useful as aldose reductase inhibitor
US4215134A (en) 4-Hydroxy-2-benzimidazoline-thione compounds and pharmaceutical compositions containing them
US4923896A (en) N-(substituted aryl)-N'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents
US5116877A (en) Pharmaceutical use for cinnamamide derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19891207

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19900605

17Q First examination report despatched

Effective date: 19910524

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930101